We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-19.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$887M
AUM Growth
+$16.2M
Cap. Flow
+$129M
Cap. Flow %
14.54%
Top 10 Hldgs %
50.79%
Holding
136
New
23
Increased
31
Reduced
31
Closed
36

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$34.3M
2
AZN icon
AstraZeneca
AZN
+$20.1M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$14.8M
4
VTRS icon
Viatris
VTRS
+$11.4M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$44.9M
2
MRK icon
Merck
MRK
+$22.8M
3
GSK icon
GSK
GSK
+$21.9M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.53M
5
V icon
Visa
V
+$6.06M

Sector Composition

Rank Sector Weight
1 Healthcare 60.28%
2 Technology 12.21%
3 Industrials 2.92%
4 Consumer Discretionary 0.53%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$194M 21.84%
2,700,000
+1,600,000
+145% +$129M
VTRS icon
2
Viatris
VTRS
$20.4B
$46M 5.18%
1,677,241
+352,241
+27% +$11.4M
MRK icon
3
Merck
MRK
$322B
$36.1M 4.07%
494,656
-322,784
-39% -$22.8M
BMY icon
4
Bristol-Myers Squibb
BMY
$133B
$32.7M 3.69%
630,000
+90,000
+17% +$4.84M
CELG
5
DELISTED
Celgene Corp
CELG
$29.8M 3.36%
+465,000
New +$34.3M
CSTE icon
6
Caesarstone
CSTE
$72.3M
$23.8M 2.68%
469,160
-92,151
-16% -$1.43M
VRNT
7
DELISTED
Verint Systems
VRNT
$23.6M 2.66%
292,683
-2,014
-0.7% -$46.3K
FOLD
8
DELISTED
Amicus Therapeutics
FOLD
$23.5M 2.64%
2,447,994
+660,000
+37% +$7.25M
GILD icon
9
Gilead Sciences
GILD
$162B
$21.9M 2.47%
350,000
-70,000
-17% -$4.89M
AZN icon
10
AstraZeneca
AZN
$263B
$19.6M 2.2%
+257,500
New +$20.1M
MSFT icon
11
Microsoft
MSFT
$3.45T
$17.8M 2.01%
46,998
-22,658
-33% -$2.43M
PANW icon
12
Palo Alto Networks
PANW
$270B
$17.5M 1.97%
+149,310
New +$4.66M
ALXN
13
DELISTED
Alexion Pharmaceuticals
ALXN
$16.4M 1.84%
168,100
+26,400
+19% +$3.12M
ITRN icon
14
Ituran Location and Control
ITRN
$1.09B
$14.6M 1.65%
+122,177
New +$4.11M
BLUE
15
DELISTED
bluebird bio
BLUE
$13.8M 1.55%
10,715
+4,663
+77% +$7.15M
ALLT icon
16
Allot
ALLT
$372M
$13.5M 1.52%
595,764
+219,313
+58% +$1.44M
SRPT icon
17
Sarepta Therapeutics
SRPT
$1.57B
$12.7M 1.43%
116,517
+40,401
+53% +$5.05M
RETA
18
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12.4M 1.4%
221,269
+128,550
+139% +$7.85M
PTCT icon
19
PTC Therapeutics
PTCT
$5.64B
$11.9M 1.34%
345,500
+135,500
+65% +$4.87M
GSK icon
20
GSK
GSK
$104B
$11.8M 1.34%
248,000
-444,000
-64% -$21.9M
TEVA icon
21
Teva Pharmaceuticals
TEVA
$40.8B
$10.9M 1.22%
704,500
+504,500
+252% +$10.3M
ALDX icon
22
Aldeyra Therapeutics
ALDX
$92.9M
$10.2M 1.15%
1,232,089
+90,000
+8% +$922K
IMMU
23
DELISTED
Immunomedics Inc
IMMU
$10.1M 1.14%
706,539
+7,500
+1% +$149K
SAGE
24
DELISTED
Sage Therapeutics
SAGE
$9.91M 1.12%
103,500
+43,500
+73% +$4.98M
MLNX
25
DELISTED
Mellanox Technologies, Ltd.
MLNX
$9.79M 1.1%
28,351
-21,742
-43% -$1.85M
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sphera Funds Management held 136 positions worth $887M, up 1.9% from $871M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Sphera Funds Management deployed $129M of net new capital in Q4 2018, opening 23 new positions and adding to 31 existing holdings. Its largest new stake was Celgene Corp: 465,000 shares worth $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 75% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $22.8M trimmed.

  • Sphera Funds Management's largest Q4 2018 buy was Celgene Corp: 465,000 shares worth $29.8M.
  • Sphera Funds Management added most to Viatris in Q4 2018, an estimated $11.4M increase.
  • Sphera Funds Management's biggest Q4 2018 reduction was Merck, cutting an estimated $22.8M.
  • Sphera Funds Management fully exited Johnson & Johnson in Q4 2018, selling an estimated $44.9M.
  • Sphera Funds Management's ten largest holdings make up 51% of its $887M portfolio in Q4 2018.
  • Sphera Funds Management opened 23 new positions and closed 36 in Q4 2018.
  • Sphera Funds Management's portfolio value rose 1.9% quarter-over-quarter to $887M.

Based on Sphera Funds Management's 13F filing for Q4 2018, filed 14 Feb 2019.